体外灌注的人胎盘对放射性标记的精氨酸加压素（125I - AVP）的降解作用。

Degradation of radiolabelled arginine vasopressin (125I-AVP) by the human placenta perfused in vitro.

作者信息

Landon M J, Copas D K, Shiells E A, Davison J M

机构信息

Section of Perinatal and Child Health, Clinical Research Centre, Harrow, Middlesex.

出版信息

Br J Obstet Gynaecol. 1988 May;95(5):488-92. doi: 10.1111/j.1471-0528.1988.tb12802.x.

DOI:10.1111/j.1471-0528.1988.tb12802.x

PMID:3401435

Abstract

The capacity of the human placenta to degrade 125I-labelled arginine vasopressin (125I-AVP) was studied in vitro using a dual circuit perfused lobule preparation. Seven placentas were perfused with the perfusate on the maternal side of the lobule containing 125I-AVP at the upper limit of the physiological range. On average, over a 30-min period, 48% of the 125I-AVP appeared to have been metabolized. With one exception, a patient whose labour was augmented with intravenous oxytocin, no 125I-AVP apparently crossed the placental lobule to the fetal circulation. These data indicate that the human placenta has a considerable capacity to degrade AVP.

摘要

利用双回路灌注小叶制备物，在体外研究了人胎盘降解¹²⁵I标记的精氨酸加压素（¹²⁵I-AVP）的能力。用含有处于生理范围上限的¹²⁵I-AVP的灌注液灌注小叶母体侧的七个胎盘。平均而言，在30分钟的时间段内，¹²⁵I-AVP的48%似乎已被代谢。除了一名通过静脉注射催产素加强宫缩的患者外，没有¹²⁵I-AVP明显穿过胎盘小叶进入胎儿循环。这些数据表明，人胎盘具有相当大的降解AVP的能力。